PR domain zinc finger protein 2 (PRDM2)

PR domain zinc finger protein 2 (PRDM2) is a histone and protein methyltransferase encoded by the PRDM2 gene. It contains a conserved N-terminal PR domain, structurally and functionally related to the SET domain found in many chromatin-modifying enzymes, and several C2H2 zinc finger domains that mediate DNA and protein binding. PRDM2 exists in two major isoforms: RIZ1 (containing the PR domain) and RIZ2 (lacking the PR domain). RIZ1 functions predominantly as a tumor suppressor and can regulate gene transcription, partially by interacting with important cell cycle regulators such as the retinoblastoma protein and estrogen receptor, and acting through methylation of histones. An imbalance of RIZ1/RIZ2 expression is implicated in the development of multiple cancers, with RIZ1 often lost or silenced in malignant cells and RIZ2 upregulated. PRDM2 is also involved in cell proliferation-differentiation switches (notably in muscle), apoptosis, and interacts with hormone signaling. Besides direct implications in cancer, it potentially contributes to the regulation of developmental and differentiation processes in other tissues. There are currently no approved drugs that specifically target PRDM2, but it remains a candidate for epigenetic therapy and biomarker development.

Other names

Retinoblastoma protein-interacting zinc finger proteinRIZRIZ1 (PRDM2a)RIZ2 (PRDM2b)KMT8KMT8ALysine N-methyltransferase 8MTB-ZFHUMHOXY1GATA-3 binding protein G3BMTE-binding proteinZinc finger protein RIZPR domain-containing protein 2

Estradiol modulates PRDM2 expression/activity via hormone receptor binding. Small molecule or gene therapy strategies aim to restore PRDM2/RIZ1 activity or compensate for loss in tumors. Epigenetic agents (DNA methylation inhibitors, histone deacetylase inhibitors) may indirectly affect PRDM2-driven pathways.